<SUBMISSION>
<ACCESSION-NUMBER>0001144204-05-032823
<TYPE>6-K
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20051027
<FILING-DATE>20051027
<DATE-OF-FILING-DATE-CHANGE>20051027
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>pSivida LTD
<CIK>0001314102
<ASSIGNED-SIC>3826
<IRS-NUMBER>000000000
<STATE-OF-INCORPORATION>C3
<FISCAL-YEAR-END>0630
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>6-K
<ACT>34
<FILE-NUMBER>000-51122
<FILM-NUMBER>051158326
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
<PHONE>61 8 9226 5099
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v027830_6k.htm
<TEXT>
<html>
  <head>
    <title>
      Unassociated Document
</title>
</head>
  <body bgcolor="#ffffff">
    <div><br>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><a name="return"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
        AND EXCHANGE COMMISSION</strong></font></a></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Washington,
        D.C. 20549</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>FORM
        6-K</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">REPORT
        OF
        FOREIGN ISSUER</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
        to Rule 13a-16 or 15d-16 of</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
        Securities Exchange Act of 1934</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>For
        the month of October 2005</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Commission
        File Number 000-51122</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>pSivida
        Limited</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Translation
        of registrant&#8217;s name into English) </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Level
        12
        BGC Centre</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">28
        The
        Esplanade</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Perth
        WA
        6000</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
        of principal executive offices)</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Indicate
        by check mark whether the registrant files or will file annual reports under
        cover Form&#160;20-F or Form&#160;40-F). </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
        20-F
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#253;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form
        40-F </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
        by check mark if the registrant is submitting the Form 6-K in paper as permitted
        by Regulatio</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">n
        S-T
        Rule 101(b)(1):</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
        by check mark if the registrant is submitting the Form 6-K in paper as permitted
        by Regulation S-T Rule 101(b)(7):</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
        by check mark whether the registrant by furnishing the information contained
        in
        this Form is also thereby furnishing the information to the Commission pursuant
        to Rule&#160;12g3-2(b) under the Securities Exchange Act of 1934.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes
        </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No
        </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#253;</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
        "Yes"
        is marked, indicate below the file number assigned to the registrant in
        connection with Rule&#160;12g3-2(b): 82- ___. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SIGNATURE
        </strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
        to the requirements of the Securities Exchange Act of 1934, the registrant,
        pSivida Limited, has duly caused this report to be signed on its behalf by
        the
        undersigned, thereunto duly authorized. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">
        <table align="center" bgcolor="#ffffff" border="0" cellpadding="0" cellspacing="0" width="100%">

            <tr valign="top" bgcolor="#ffffff">
              <td width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Date:
                October 27, 2005</font></td>
              <td width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td colspan="2">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
                  Limited</font></div>
              </td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<br>&#160;</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<br>&#160;</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<br>&#160;</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td>&#160;</td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">By:&#160;&#160;</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">/s/&#160;Aaron
                Finlay</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td colspan="2"><font style="FONT-FAMILY: Times New Roman" size="1">&#160;</font></td>
              <td align="left">
                <hr style="COLOR: #000000" align="left" noshade size="2" width="80%"><font size="2">Aaron
                Finlay</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Chief
                Financial Officer and Company
                Secretary</em></font></td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 225pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 100.65pt" align="left">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">&#160;</div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 225pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u>EXHIBIT
        INDEX</u></em></strong></font></div>
      <div>
        <table cellpadding="0" cellspacing="0" width="100%">

            <tr>
              <td align="left" valign="top" width="15%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>EXHIBIT
                  99.1:</strong></font></div>
              </td>
              <td align="left" valign="top" width="62%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Beijing
                  Med-Pharm Licence</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">&#160;</div>
        </div>
        <div id="PN">
          <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">-
            2
            -</font></div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">&#160;</div>
        </div>
      </div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v027830_ex99-1.htm
<TEXT>
<html>
  <head>
    <title>
      Unassociated Document
</title><!-- Licensed to: vf-->
<!-- Document Created using EDGARIZER HTML 3.0.0.39895 -->
<!-- Copyright 2005 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff">
    <div><br>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><br></div>
      <div align="center">
        <table bgcolor="#ffffff" cellpadding="0" cellspacing="0" width="100%">

            <tr bgcolor="#ffffff">
              <td valign="middle" width="50%"><strong><font size="2">ASX/MEDIA
                RELEASE</font></strong></td>
              <td width="50%">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><img src="psivida.jpg" alt=""></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="right"><font id="TAB2" style="COLOR: black; LETTER-SPACING: 0.9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;27
        October 2005</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 24pt; FONT-FAMILY: Times New Roman"><strong>Beijing
        Med-Pharm Licence</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">Upfront
        and milestone payments</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">BrachySil</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">
        entry
        point for China</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center">
        <div>
          <hr style="COLOR: #000000" align="left" noshade size="1" width="100%">
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Global
        bio-nanotech company pSivida Limited </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(ASX:PSD,
        NASDAQ:PSDV, Xetra:PSI)</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        is
        pleased to announce that it has signed a Licence with Beijing Med-Pharm
        Corporation </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(BJGP:PK)</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        for the
        clinical development, marketing and distribution of pSivida&#8217;s lead product,
        BrachySil</font><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Arial, sans-serif"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
        in
        China. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Under
        the
        terms of the Licence, pSivida will manufacture BrachySil</font><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Arial, sans-serif"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        and
        Beijing Med-Pharm will be responsible for clinical development, securing
        regulatory approval, marketing and distribution in China. pSivida will retain
        manufacturing rights for BrachySil</font><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Arial, sans-serif"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        under
        the Licence. It is a condition of the licence that a Manufacturing and Supply
        Agreement for pSivida to supply BrachySil</font><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Arial, sans-serif"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        to
        Beijing Med-Pharm is concluded within 90 days.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Licence includes upfront and milestone payments in excess of US$2 million
        and
        royalties ranging up to 30%, depending upon level of sales, payable to pSivida
        by Beijing Med-Pharm. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Beijing
        Med-Pharm is a US-based company with Chinese subsidiaries that offers an
        end-to-end solution to primarily Western pharmaceutical companies who wish
        to
        sell their products into the Chinese marketplace. In December 2004, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>Beijing
        Med-Pharm initiated the first ever purchase of a </u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Chinese
        pharmaceutical distribution company by a foreign entity</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>
        after
        it signed an agreement to purchase Beijing Wanwei Pharmaceutical
        Ltd.</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
        a
        pharmaceutical distributor covering the bulk of Beijing's
        hospitals.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BrachySil</font><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Arial, sans-serif"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        (32-P
        BioSilicon&#8482;) will enter a Phase IIb dose-profiling study shortly as a potential
        new treatment for primary liver cancer (also called hepatocellular carcinoma
        or
        HCC). China has the highest incidence of HCC in the world, with over 345,000
        estimated new cases per annum (Globocan), representing 55% of total worldwide
        cases. Given the clinical proof of principle already established for
        BrachySil</font><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Arial, sans-serif"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
        focused
        programmes are being prepared to exploit its broader utility in other
        significant cancer indications, including inoperable pancreatic and secondary
        liver disease. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Gavin
        Rezos, CEO of pSivida said, &#8220;China is the world&#8217;s fastest growing market for
        pharmaceuticals with a large and steadily increasing incidence of the types
        of
        cancer that we believe BrachySil</font><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Arial, sans-serif"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        can
        effectively treat. Gaining entry into this market, through partners such
        as
        Beijing Med-Pharm, is an important part of pSivida&#8217;s global commercial strategy.
</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
        agreement clearly validates the commercial potential of the
        BrachySil</font><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman, serif"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        product
        and technology, and will serve as a robust platform for further licensing
        agreements for BrachySil</font><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman, serif"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        in other
        territories, including Europe and the United States&#8221;.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Martyn
        Greenacre, Chairman of Beijing Med-Pharm said, &#8220;BrachySil</font><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Arial, sans-serif"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        is a
        highly innovative product addressing a significant patient population in
        China
        and thus an important addition to our portfolio of products to be
        commercialized. The growing middle class in China allows for a growing and
        significant population with the ability to pay for medicines of this
        type&#8221;.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
        Limited recently announced that it had entered into a definitive merger
        agreement to acquire Control Delivery Systems, a US based drug delivery company
        with the potential to create a global bio-nanotech company specializing in
        drug
        delivery, with revenues from existing products and generating long-term value
        through its diversified late-stage product portfolio. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>-ENDS-</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
          </div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Released
        by:</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div>
        <table cellpadding="0" cellspacing="0" width="100%">

            <tr>
              <td align="left" valign="top" width="26%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>pSivida
                  Limited</strong></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Brian
                  Leedman</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Investor
                  Relations</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
                  Limited</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                  + 61 8 9226 5099</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">brianl@psivida.com</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Beijing
                  Med-Pharm Corporation</strong></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Ben
                  Austin</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                  +1 (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">917</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">)
                  686-3979 </font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>baustin@beijingmedpharm.com</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></div>
              </td>
              <td align="left" valign="top" width="26%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>US
                  Public Relations</strong></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Beverly
                  Jedynak</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">President</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Martin
                  E. Janis &amp; Company, Inc</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                  +1 (312) 943 1100 ext. 12</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">bjedynak@janispr.com</font></div>
              </td>
              <td align="left" valign="top" width="28%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>UK
                  &amp; Europe Public</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Relations</strong></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Mark
                  Swallow / Helena Podd</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Citigate
                  Dewe Rogerson</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                  +44 (0)20 7638 9571</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">mark.swallow@citigatedr.co.uk</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>NOTES
        TO EDITORS:</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>pSivida
        Limited</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
        is a global bio-nanotech company committed to the biomedical sector and the
        development of products in healthcare. The company&#8217;s focus is the development
        and commercialisation of a modified form of silicon (porosified or
        nano-structured silicon) known as BioSilicon&#8482;. As a new and exciting
        biocompatible material, BioSilicon&#8482; offers multiple potential applications
        across the high growth healthcare sector, including controlled release drug
        delivery, targeted cancer therapies (including brachytherapy and localized
        chemotherapy), tissue engineering and orthopedics. Potential diagnostics
        applications are being developed through its subsidiary AION Diagnostics
        Limited. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
        owns the intellectual property rights to BioSilicon&#8482; for use in or on humans and
        animals. The IP portfolio consists of 29 patent families, 34 granted patents
        and
        over 80 patent applications. The core patent, which recognises BioSilicon&#8482; as a
        biomaterial was granted in the UK in 2000 and in the US in 2001. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
        is listed on NASDAQ (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PSDV</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">),
        the
        Australian Stock Exchange (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PSD</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">)
        and in
        Germany on the Frankfurt Stock Exchange on the XETRA system (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>German</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Symbol:
        PSI. Securities Code (WKN) 358705</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">).
        pSivida&#8217;s shares also trade in the United Kingdom on the OFEX International
        Market Service (IMS) under the ticker symbol </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PSD</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.
        pSivida
        is a founding member of the NASDAQ Health Care Index and the Merrill Lynch
        Nanotechnology Index.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Company&#8217;s strategic partner and largest shareholder is the QinetiQ group, the
        largest science and technology company in Europe. QinetiQ is the former UK
        government Defence Evaluation Research Agency and was instrumental in
        discovering BioSilicon&#8482;. pSivida enjoys a strong relationship with QinetiQ
        having access to its cutting edge research and development facilities. For
        more
        information on QinetiQ visit </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>www.qinetiq.com</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
        more
        information, visit </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>www.psivida.com</u></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>About
        Beijing Med-Pharm Corporation</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Beijing
        Med-Pharm Corporation is a pharmaceutical marketing company that offers the
        following services in China through its wholly-owned subsidiary, Beijing
        Med-Pharm Market Calculating Co. Ltd.: pre-market entry analysis; clinical
        trial
        management; product registration; market research; and pharmaceutical marketing
        to physicians, hospitals and other healthcare providers.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">In
        December 2004, </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>Beijing
        Med-Pharm signed an agreement to purchase Beijing Wanwei Pharmaceutical
        Ltd.</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">,
        a
        pharmaceutical distributor covering the bulk of Beijing's hospitals. This
        is the
        first-ever purchase of a Chinese pharmaceutical distribution company by a
        foreign entity, permitted only after a December 2004 change in Chinese law.
        By
        adding this distributor to its existing sales and marketing services, upon
        completion of the acquisition, Beijing Med-Pharm will offer an unparalleled
        opportunity to reach China, the world's fastest-growing market.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
        more
        information, visit </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>www.beijingmedpharm.com</u></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
        document contains forward-looking statements that involve risks and
        uncertainties. Although we believe that the expectations reflected in such
        forward-looking statements are reasonable at this time, we can give no assurance
        that such expectations will prove to be correct. Given these uncertainties,
        readers are cautioned not to place undue reliance on such forward-looking
        statements. Actual results could differ materially from those anticipated
        in
        these forward-looking statements due to many important factors including:
        our
        failure to develop applications for BioSilicon</font><font style="DISPLAY: inline; FONT-SIZE: 7pt; FONT-FAMILY: Arial, sans-serif"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        due to
        regulatory, scientific or other issues. Other reasons are contained in
        cautionary statements in the Registration Statement on Form 20-F filed with
        the
        U.S. Securities and Exchange Commission, including, without limitation, under
        Item&#160;3.D, "Risk Factors" therein. We do not undertake to update any
        oral or
        written forward-looking statements that may be made by or on behalf of
        pSivida.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">
          </div>
        </div>
        <div id="PN">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
          </div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt" align="justify"><br></div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>psivida.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 psivida.jpg
M_]C_X``02D9)1@`!`@$`2`!(``#_X0H]17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````4````<@$R``(````4````AH=I``0````!````G````,@```!(````
M`0```$@````!061O8F4@4&AO=&]S:&]P(#<N,``R,#`U.C$P.C(V(#`P.C,T
M.C0X``````.@`0`#`````?__``"@`@`$`````0```-B@`P`$`````0```#T`
M````````!@$#``,````!``8```$:``4````!```!%@$;``4````!```!'@$H
M``,````!``(```(!``0````!```!)@("``0````!```)#P````````!(````
M`0```$@````!_]C_X``02D9)1@`!`@$`2`!(``#_[0`,061O8F5?0TT``O_N
M``Y!9&]B90!D@`````'_VP"$``P("`@)"`P)"0P1"PH+$14/#`P/%1@3$Q43
M$Q@1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P!#0L+#0X-
M$`X.$!0.#@X4%`X.#@X4$0P,#`P,$1$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#/_``!$(`"0`@`,!(@`"$0$#$0'_W0`$``C_Q`$_```!
M!0$!`0$!`0`````````#``$"!`4&!P@)"@L!``$%`0$!`0$!``````````$`
M`@,$!08'"`D*"Q```00!`P($`@4'!@@%`PPS`0`"$0,$(1(Q!4%181,B<8$R
M!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5
MXF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7
MI[?'U^?W$0`"`@$"!`0#!`4&!P<&!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q
M0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*S
MA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_
MV@`,`P$``A$#$0`_`/54DED]2`Q<AF30W8\$.?M$;MSMKVOCZ6Y0<SG]C'[A
MCQ1!''KK&/[R8BS3K*AU'J].%8S&95;EYMK=U6)0W<\MD,]2Q[ME&-3N/\]D
MVU5_VUE]1R\#(OM^Q.+WT6FK*L;NV>J!+J6O_F[+*/\`#^G_`#/\W9^D5Y_Z
MKTAKZ)99>VO<Z23+@-SM57//F.;/CGC`'+Q]R4A.^*)CQPX(^W\W^$GAN(,3
MN:V^U"[%ZGD5/RNLYPP,9C2]^+AOV-8QLO<[)ZB]K<BS:SZ;\?[#7_QG\XB_
M5EN:.EBS+?:X76V68K<C6YF.YQ.)7D/=NL=;Z.U[_5_35[_1L_FU.KI6)D8U
M3;6S4'A]E<`"QU;II]?_`$C*W_I-COSU9ZGU''Z7@79^2'&G';N>&#<Z)V^U
MNGBKF*9GCC(CA,@)<-\5<7];TL9B(DGI'JVDES)_QA?5YK\>3>*LB)R#4?2K
M<0"ZJVW_`$E6YOK^CZWH_P"$6EUC)NKLIH8\TLLU?:/"6CG^1.YR9S.>/+XC
MED"0*%#K*1X8I@8S-1(-.HDL[&HSZ,ENV[[1BO$N<]TG^Q]+_P`@IV?9OVM5
MN=9Z^SVM$>G$6?2_E?23!S)X!*6,XR<D<7#D-?/^ECG'BCD7\/C>EMY)9G3?
MK#@=2S<W!I%E=_3G;+VVM#1R]FZOW.WL_1_]0LK-Z_T3KOU6S\MQRZ>GUN;5
M;;4T,N)#JG_H)W_Z2O<K-,1R1JP1L3_BO4)+#PNJ](Z3]5<7/-MIP*Z6>BZX
M;KW[O;4QS6?2N?\`Z^Q<YUCZUCJ75/J^>F7Y.*RS(`RL=V^DN8^W';2;&C]%
MD4VM%VQ];[:T:1++&(!.YK3^\]^DL?KGUJZ3T2RNC*-EN5:`YF-0S?86DEN^
M/:UON;^_[T7H7UBZ9UZA]N`]TU$"VJQNU["Z=FYNK??M]KF.0I=QQXN&QQ=G
M_]#U58K\K]KYV1B8E0=CX8-5V:7';]HEI^R4M9_.^C_VIL]3]!;^A_26>O76
M;ZP/SSA-Q.G;FY&9:S'=D,$FBNPGULR!_HJFO]+_`(?TD8?LGH'3&5E]6#@8
MK0QI>X-:/[3S[[+/^W+;$S)CADA*$QQ1D*(1Q&]-*ZN9U&G)HIIJN%6UI>6&
MH$23[K'/;#6[G..[VJW7B9N51C-L=4W'8UKFM&XN.GL<_P"C[E2S<O*ZN*WX
M>-=1B-DMR;*CZE@/_<7$>/T3=/Z1GLK_`."Q,I:_3&L9C-K:RQCVM`L-H=N)
MC_26^ZQ9<.3B>=S1R3D83C#ACQ'CR<`C_.2_[GBXV3CN(H;=?^];5=;:V-8W
MAH@+&^NO_B6ZC_Q0_P"J:MM8_P!;Z+\CZM9]./6^ZU]8#*ZVESG'<WZ+&^YR
MUX@"@-`-&+)K"?\`=+Q/7"/_`!L^D\?SPC_-RUWE]V'Z./BYC238QI#B(VF-
MN[U/S5SWU?\`J3TC)Z7T_*ZEB65Y;&EUV.\O8USPX^Z_&/Y^UK-_^F_PWJ+K
M<G$HRF!ES=P'T3P1\'!1<U&<\4HX^`R/3*.+'(?I1DQ\O$@\4M+C$:;^D.76
M'].ZC7C56&RFTB:SVW::_P`K\Y&N_P"7J/\`BS^2U6<7IF)BO]2MI+^SG&2)
M\$5V)2[);E$'U6#:TR8CW?F_VU1Q\EF&,1],0,\,T<7%*<<.*$N*4(SDV3(7
M]*MX'ZV7NZ#]9<[,:#LZQTZRH.;IMMAM._\`ZWZ-+W?\:KF3T_\`9W^+`T$0
M]]-=UFD'=;;7=M=_Q>_T_P"PNEZU]7.E=<%(ZC6ZS[.7&O:]S/I[?4:[TRW<
MUVQBL]2Z=B]3P;,#+:78]P`>UI+3[2'MAS/=])BU+V:APF\FH]0(A_A_,\%]
M8Y_\;7I$>-/_`)[N5WZUNK/4OJCZ9!9ZK2W;QM-F#MV_R5U%OU?Z7;T=O1;:
MB_"K:UC&ESMPV'=6YML^IO8X?25''^HOU=QSC/958;<2P6UVNL>7ES2U];7N
MG^:KV>RG^9_[<2M1PRUJM1#_`,;:74^H/N^M)Z;T/`Q3UBJL/R>J93!^B86M
M]M>R+[7>G=5_A/\`"[/YOU?3I_4%MC>O?6!MMHOM%H%EX`:'N%F3OM:QI<UG
MJ.]^Q;W4_J=T/JF?^T,JNP9!`%AJL?6'@#9^D]-S?\'^C]G^#5CI/U<Z3T:_
M(NZ?4:3DP+&;B6`-+G,;76[VUM;O_-2O1/MS]P2-4)$_0C]U_]'L?K3]C^V8
MD?M+]H;+/3_97\YZ,L]7[3ZGZ#T?4]+9ZG^$_FT'H_\`S2^WU>IZO[9@>G^U
M_5^U3V^S_;_9N_\`""^?TD>C#_E#\OU_E\S]5)+Y5209GZJ27RJDDI^JDE\J
MI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?JI)?*J22G__9_^T.^%!H;W1O<VAO
M<"`S+C``.$))300E```````0`````````````````````#A"24T#[0``````
M$`!(`````0`!`$@````!``$X0DE-!"8```````X`````````````/X```#A"
M24T$#0``````!````'@X0DE-!!D```````0````>.$))30/S```````)````
M```````!`#A"24T$"@```````0``.$))32<0```````*``$``````````3A"
M24T#]0``````2``O9F8``0!L9F8`!@```````0`O9F8``0"AF9H`!@``````
M`0`R`````0!:````!@```````0`U`````0`M````!@```````3A"24T#^```
M````<```_____________________________P/H`````/______________
M______________\#Z`````#_____________________________`^@`````
M_____________________________P/H```X0DE-!`````````(``3A"24T$
M`@``````!``````X0DE-!`@``````!`````!```"0````D``````.$))300>
M```````$`````#A"24T$&@`````#20````8``````````````#T```#8````
M"@!5`&X`=`!I`'0`;`!E`&0`+0`Q`````0`````````````````````````!
M``````````````#8````/0`````````````````````!````````````````
M`````````!`````!````````;G5L;`````(````&8F]U;F1S3V)J8P````$`
M``````!28W0Q````!`````!4;W`@;&]N9P``````````3&5F=&QO;F<`````
M`````$)T;VUL;VYG````/0````!29VAT;&]N9P```-@````&<VQI8V5S5FQ,
M<P````%/8FIC`````0``````!7-L:6-E````$@````=S;&EC94E$;&]N9P``
M```````'9W)O=7!)1&QO;F<`````````!F]R:6=I;F5N=6T````,15-L:6-E
M3W)I9VEN````#6%U=&]'96YE<F%T960`````5'EP965N=6T````*15-L:6-E
M5'EP90````!);6<@````!F)O=6YD<T]B:F,````!````````4F-T,0````0`
M````5&]P(&QO;F<``````````$QE9G1L;VYG``````````!"=&]M;&]N9P``
M`#T`````4F=H=&QO;F<```#8`````W5R;%1%6%0````!````````;G5L;%1%
M6%0````!````````37-G951%6%0````!```````&86QT5&%G5$585`````$`
M``````YC96QL5&5X=$ES2%1-3&)O;VP!````"&-E;&Q497AT5$585`````$`
M``````EH;W)Z06QI9VYE;G5M````#T53;&EC94AO<GI!;&EG;@````=D969A
M=6QT````"79E<G1!;&EG;F5N=6T````/15-L:6-E5F5R=$%L:6=N````!V1E
M9F%U;'0````+8F=#;VQO<E1Y<&5E;G5M````$453;&EC94)'0V]L;W)4>7!E
M`````$YO;F4````)=&]P3W5T<V5T;&]N9P`````````*;&5F=$]U='-E=&QO
M;F<`````````#&)O='1O;4]U='-E=&QO;F<`````````"W)I9VAT3W5T<V5T
M;&]N9P``````.$))3001```````!`0`X0DE-!!0```````0````".$))300,
M``````DK`````0```(`````D```!@```-@````D/`!@``?_8_^``$$I&248`
M`0(!`$@`2```_^T`#$%D;V)E7T--``+_[@`.061O8F4`9(`````!_]L`A``,
M"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,#!$,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.%!0.#@X.%!$,#`P,
M#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"``D
M`(`#`2(``A$!`Q$!_]T`!``(_\0!/P```04!`0$!`0$``````````P`!`@0%
M!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)"@L0``$$`0,"!`(%
M!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<E
MDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D
M]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$``@(!`@0$`P0%!@<'
M!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q
M)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75
MY?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1`Q$`/P#U5))9/4@,
M7(9DT-V/!#G[1&[<[:]KX^EN4',Y_8Q^X8\401QZZQC^\F(LTZRH=1ZO3A6,
MQF56Y>;:W=5B4-W/+9#/4L>[91C4[C_/9-M5?]M9?4<O`R+[?L3B]]%IJRK&
M[MGJ@2ZEK_YNRRC_``_I_P`S_-V?I%>?^J](:^B667MKW.DDRX#<[55SSYCF
MSXYXP!R\?<E(3OBB8\<."/M_-_A)X;B#$[FMOM0NQ>IY%3\KK.<,#&8TO?BX
M;]C6,;+W.R>HO:W(LVL^F_'^PU_\9_.(OU9;FCI8LRWVN%UMEF*W(UN9CN<3
MB5Y#W;K'6^CM>_U?TU>_T;/YM3JZ5B9&-4VULU!X?97``L=6Z:?7_P!(RM_Z
M38[\]6>I]1Q^EX%V?DAQIQV[GA@W.B=OM;IXJYBF9XXR(X3("7#?%7%_6]+&
M8B))Z1ZMI)<R?\87U>:_'DWBK(B<@U'TJW$`NJMM_P!)5N;Z_H^MZ/\`A%I=
M8R;J[*:&/-++-7VCPEHY_D3N<F<SGCR^(Y9`D"A0ZRD>&*8&,S42#3J)+.QJ
M,^C);MN^T8KQ+G/=)_L?2_\`(*=GV;]K5;G6>OL]K1'IQ%GTOY7TDP<R>`2E
MC.,G)'%PY#7S_I8YQXHY%_#XWI;>269TWZPX'4LW-P:197?TYVR]MK0T<O9N
MK]SM[/T?_4+*S>O]$Z[]5L_+<<NGI];FU6VU-#+B0ZI_Z"=_^DKW*S3$<D:L
M$;$_XKU"2P\+JO2.D_57%SS;:<"NEGHNN&Z]^[VU,<UGTKG_`.OL7.=8^M8Z
MEU3ZOGIE^3BLLR`,K'=OI+F/MQVTFQH_19%-K1=L?6^VM&D2RQB`3N:T_O/?
MI+'ZY]:ND]$LKHRC9;E6@.9C4,WV%I);OCVM;[F_O^]%Z%]8NF=>H?;@/=-1
M`MJL;M>PNG9N;JWW[?:YCD*7<<>+AL<79__0]56*_*_:^=D8F)4'8^&#5=FE
MQV_:):?LE+6?SOH_]J;/4_06_H?TEGKUUF^L#\\X3<3IVYN1F6LQW9#!)HKL
M)];,@?Z*IK_2_P"'])&'[)Z!TQE9?5@X&*T,:7N#6C^T\^^RS_MRVQ,R8X9(
M2A,<49"B$<1O32NKF=1IR:*::KA5M:7EAJ!$D^ZQSVPUNYSCN]JMUXF;E48S
M;'5-QV-:YK1N+CI['/\`H^Y4LW+RNKBM^'C748C9+<FRH^I8#_W%Q'C]$W3^
MD9[*_P#@L3*6OTQK&8S:VLL8]K0+#:';B8_TEONL67#DXGG<T<DY&$XPX8\1
MX\G`(_SDO^YXN-DX[B*&W7_O6U76VMC6-X:("QOKK_XENH_\4/\`JFK;6/\`
M6^B_(^K6?3CUONM?6`RNMI<YQW-^BQON<M>(`H#0#1BR:PG_`'2\3UPC_P`;
M/I/'\\(_S<M=Y?=A^CCXN8TDV,:0XB-IC;N]3\U<]]7_`*D](R>E]/RNI8EE
M>6QI==CO+V-<\./NOQC^?M:S?_IO\-ZBZW)Q*,I@9<W<!]$\$?!P47-1G/%*
M./@,CTRCBQR'Z49,?+Q(/%+2XQ&F_I#EUA_3NHUXU5ALIM(FL]MVFO\`*_.1
MKO\`EZC_`(L_DM5G%Z9B8K_4K:2_LYQDB?!%=B4NR6Y1!]5@VM,F(]WYO]M4
M<?)9AC$?3$#/#-'%Q2G'#BA+BE",Y-DR%_2K>!^ME[N@_67.S&@[.L=.LJ#F
MZ;;8;3O_`.M^C2]W_&JYD]/_`&=_BP-!$/?37=9I!W6VUW;7?\7O]/\`L+I>
MM?5SI77!2.HUNL^SEQKVO<SZ>WU&N],MW-=L8K/4NG8O4\&S`RVEV/<`'M:2
MT^TA[8<SW?28M2]FH<)O)J/4"(?X?S/!?6.?_&UZ1'C3_P">[E=^M;JSU+ZH
M^F06>JTMV\;39@[=O\E=1;]7^EV]';T6VHOPJVM8QI<[<-AW5N;;/J;V.'TE
M1Q_J+]7<<XSV56&W$L%M=KK'EY<TM?6U[I_FJ]GLI_F?^W$K4<,M:K40_P#&
MVEU/J#[OK2>F]#P,4]8JK#\GJF4P?HF%K?;7LB^UWIW5?X3_``NS^;]7TZ?U
M!;8WKWU@;;:+[1:!9>`&A[A9D[[6L:7-9ZCO?L6]U/ZG=#ZIG_M#*KL&00!8
M:K'UAX`V?I/3<W_!_H_9_@U8Z3]7.D]&OR+NGU&DY,"QFXE@#2YS&UUN]M;6
M[_S4KT3[<_<$C5"1/T(_=?_1['ZT_8_MF)'[2_:&RST_V5_.>C+/5^T^I^@]
M'U/2V>I_A/YM!Z/_`,TOM]7J>K^V8'I_M?U?M4]OL_V_V;O_``@OG])'HP_Y
M0_+]?Y?,_522^54D&9^JDE\JI)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?JI)?
M*J22GZJ27RJDDI__V0`X0DE-!"$``````%4````!`0````\`00!D`&\`8@!E
M`"``4`!H`&\`=`!O`',`:`!O`'`````3`$$`9`!O`&(`90`@`%``:`!O`'0`
M;P!S`&@`;P!P`"``-P`N`#`````!`#A"24T$!@``````!P`&`````0$`_^$2
M2&AT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\`/#]X<&%C:V5T(&)E9VEN
M/2?ON[\G(&ED/2=7-4TP37!#96AI2'IR95-Z3E1C>FMC.60G/SX*/#]A9&]B
M92UX87`M9FEL=&5R<R!E<V,](D-2(C\^"CQX.GAA<&UE=&$@>&UL;G,Z>#TG
M861O8F4Z;G,Z;65T82\G('@Z>&%P=&L])UA-4"!T;V]L:VET(#(N."XR+3,S
M+"!F<F%M97=O<FL@,2XU)SX*/')D9CI21$8@>&UL;G,Z<F1F/2=H='1P.B\O
M=W=W+G<S+F]R9R\Q.3DY+S`R+S(R+7)D9BUS>6YT87@M;G,C)R!X;6QN<SII
M6#TG:'1T<#HO+VYS+F%D;V)E+F-O;2]I6"\Q+C`O)SX*"B`\<F1F.D1E<V-R
M:7!T:6]N(&%B;W5T/2=U=6ED.CED8S,R9&4R+30U9#DM,3%D82UB,V)E+3DQ
M.30Q86%A9#9E92<*("!X;6QN<SIX87!-33TG:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87`O,2XP+VUM+R<^"B`@/'AA<$U-.D1O8W5M96YT240^861O8F4Z9&]C
M:60Z<&AO=&]S:&]P.CED8S,R9&4P+30U9#DM,3%D82UB,V)E+3DQ.30Q86%A
M9#9E93PO>&%P34TZ1&]C=6UE;G1)1#X*(#PO<F1F.D1E<V-R:7!T:6]N/@H*
M/"]R9&8Z4D1&/@H\+W@Z>&%P;65T83X*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"CP_>'!A8VME="!E;F0])W<G/S[_
M[@`.061O8F4`9$`````!_]L`A``"`@("`@("`@("`P("`@,$`P("`P0%!`0$
M!`0%!@4%!04%!08&!P<(!P<&"0D*"@D)#`P,#`P,#`P,#`P,#`P,`0,#`P4$
M!0D&!@D-"@D*#0\.#@X.#P\,#`P,#`\/#`P,#`P,#PP,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`S_P``1"``]`-@#`1$``A$!`Q$!_]T`!``;_\0!H@``
M``<!`0$!`0``````````!`4#`@8!``<("0H+`0`"`@,!`0$!`0`````````!
M``(#!`4&!P@)"@L0``(!`P,"!`(&!P,$`@8"<P$"`Q$$``4A$C%!408382)Q
M@10RD:$'%;%"(\%2T>$S%F+P)'*"\25#-%.2HK)C<\(U1">3H[,V%U1D=,/2
MX@@F@PD*&!F$E$5&I+16TU4H&O+C\\34Y/1E=865I;7%U>7U9G:&EJ:VQM;F
M]C='5V=WAY>GM\?7Y_<X2%AH>(B8J+C(V.CX*3E)66EYB9FIN<G9Z?DJ.DI:
M:GJ*FJJZRMKJ^A$``@(!`@,%!00%!@0(`P-M`0`"$0,$(1(Q0051$V$B!G&!
MD3*AL?`4P='A(T(54F)R\3,D-$."%I)3):)CLL('<](UXD2#%U23"`D*&!DF
M-D4:)V1T53?RH[/#*"G3X_.$E*2TQ-3D]&5UA96EM<75Y?5&5F9VAI:FML;6
MYO9'5V=WAY>GM\?7Y_<X2%AH>(B8J+C(V.CX.4E9:7F)F:FYR=GI^2HZ2EIJ
M>HJ:JKK*VNKZ_]H`#`,!``(1`Q$`/P#[^8J[%78J[%78J[%6/>:?-GEGR1HE
MYYD\WZ[9>7-"T]>5WJE_,L,*>`Y,15CV4;GL,(!.P:L^?'@@9Y)",1U+YBM?
MSW_-+\WG9/\`G'G\N8U\K,Q1/S<\]^OI^E2CIZFGZ?&!=70[ACP6NQRWPXQ^
MH_`.DCVIJ-9_BF/T_P`^=B/PCS+R_P#.K7?^<G_R&T/RQ^8-U^=&F_F%+J/F
M33=%N/RX3RS::?:W;7S,!#;7"227-?@(!+5[]J&>,0GM5>=N#VED[1T$8YCF
M&2Y`<'``#?0'F_0Q"S(I=>#$`LE:T/<5S&>N"[%78J[%78J[%78J[%78J[%7
M8J[%78J[%78J[%78J[%7_]#[^8JIRR+#%),P)6)"[!14D**F@RO+D&.!F>0!
M.W/9(%O/;#\T_*=[=06DLMWI4MRW"W;4+=X$=JTIS-5'TG.`T/\`P3^QM3FC
MAG*>&4S4?%@81)[N+<#XD!RI:+(!>Q]S,=8UK3-`L7U+5KH6EE&RH\Y5GH7-
M%%$!.Y]LZ_MCMG2=D:<ZG5SX,8(!-$[G8;1!/V./CQRR&H[EB/\`RM;R#_U?
MU_Y$3_\`5/.1_P"3J^S?_*4/])D_XAR/R.;^;]S'/,_YG/?:8VG?E?J&A:CY
MTU"1;?2(O,#7UM8J[[!I#;VTCM0]%'&O\PS,[/\`^"/[/ZW40P8M3Q3F1&(X
M)[D[`68@#XN+K-)JX8R<48\7]([?99>-VGY`:/#>6OYD?\Y/^=V_-KS5:R"3
M3='NHS%Y9TR8[B/3M)4%96'3G*K$]2H.^=+VY[1:+L73G/JL@Q8^7>9'N`%D
MGR'W.DTG8$L^03U,O&GW?P1]T>7Q//N?2OEKSIH6O2RV&EVEW9Q:?;"4-<6Q
MMX%B4A0$)V%`=AX9HO9_VTT7;F:6+3PR@QCQ7.!C$BP-B>N[T.73'#&S5/G+
M1='N?^<BOS7T7\T=1!7\E_RHNYA^5=DXH/,&MJ3%/KC`];:`@I:G]L@R#X3O
MVA/!&NIYO+XL9[1U(SG^YQGT?TY?S_</X?F^PLI>A=BKL5=BJ3W7F+0+*8V]
MYK=A:S@T,,US$CCYJS`YI]3[0]FZ6?AYM3BA+NE.(/R)MLCBG(6`?DF<,T-Q
M&LUO*D\+BJ2QL&4CV(J#FTPYH9HB>.0E$\B#8/Q#`@CFAM3U.QT>QN-2U*X%
MK96H#7$Y!(4$A1LH)ZD=LQ>TNTM/V=IY:G4RX,<.9W-60.EGF0F$#,T.:`T/
MS+H?F2.XFT2_6_CM7"7#*KKQ9A4#XU7MF#V)[2=G]M0E/191D$"`:!%$\OJ`
M99,,\?U"D]S>-;L52G7M<TKRQHFK^8]=O%T_1=!LY]0U:^=698;:V0R2R%4#
M,0JJ30`G"!9H->7+'%`SF:C$63Y!YS^6OY[_`)3?G!=:K8_EQYQ@\SW6B0Q3
MZI##!<PF*.9F6-B9XHP:E3TKDI8Y1YAP]%VIIM82,,^(CGL?TAZYD'8(._U'
M3]*M);_5+ZWTVQ@IZ][=2I#$G(A1R=R%%20!4]<0+8SG&`N1`'FA=*U[0M>2
M:70]:L-9CMV"7$EC<Q7"QLPJ`QB9@"1XX2".;''EAD^B0/N-IM@;'8J[%7__
MT?OYBKL5?/OYN6$=U<789"[K:+<0L5U&3@Z5!X+&K6RU"T):GB<^?_\`@M:"
M.?+.Q9&,3&VHE1%_2("6GC8C7JH]95L7:Z"5`>_R_M9E^6NM1ZKY"M;G698V
MCTGU;>\N;HKP$=M\0>1GV`6,BI/A7.X_X%_:1[7]G\7YCURQDXS>]\'TW?\`
M1,1\'%UT1BR$\AS?-GG^_P!%U;S+-J_ER>VN]#U>TL[W3+VSIZ$\4T".LL94
M`$.#6O?KGSQ_P6--CT_M'J(8XB`J&P``LPC>P^UVG9N49=/&<38/(]X?0WY-
M65F?)EI<FUA-RUU<$W!1>9*O0?%2NP&>Y_\``<T>`]@X\O!'C,Y^JAQ;';?G
MLZ_M"1\4B^CS;\P+R37OS'.F7'[W3M#B58[9EN)$+&-9')6U5I`2S`5`[#/.
M/;_62[6]J3I<F^+3Q`$2,DHWPB4C6$2R`F4@+`_A%ER]+'P\'$.9]WZ7K\7E
MJ'S5Y,L-#U&YF71-15_T[:1O<J]Y`7;E;-)<TG6*0;2#8E?A!"G/H+V1'!V9
MA.]D$[G(?XC_`*O^]_TW+IM3I==A&8F!^D\^6X[MNAZT]`M;6VL;:WLK*VBL
M[.SB2"TM($6.***-0J(B*`%50```*`9T*(Q$0`!0"4>9_-'E_P`F:#J/F?S5
MJUOH7E_2$634M6NFX0PHSK&I=MZ59@/IP@$F@UYL\,,#.9J(YEY[9?G_`/DM
MJ'E;5O.UG^9>A3>5-"N%M-5UWZRJP17#()%AJU"SLIJ%4$GL,EX<KJG$CVKI
M98SD&2/"-B;Z]R*_+K\\?RE_-F:]MOR\\]Z;YFO-.427MA`SQ7*1DT$GH3K'
M(4KMR"T]\98Y1YA.C[3TVKL89B1'3K\CNAOSD\R7^AZ!:6FFS/:SZS.T4MS&
M>+K#&O)PI&X+$@5':N>/_P#!B]H]3V5V9#%II&$L\C$R&Q$(BY`'H38%]UN^
M[/PB<R3T>2^2?RI?S?HDFM3:P+#U99([6)8O5),9H6D)9:5/;/)_8O\`X%<O
M:/L\ZV>H\/B)$1P\7T\S(V*WZ?%SM3KO!GP@6F/Y?6GGCRIYN?28]-N[G2DN
M?JVLHBM]5XG83H[46H!#"FY&V;'_`('^C]H?9_MLZ08<D\`GP9:!\*NF2,C4
M;'U"MS':F&JEBRX^*Q?3O]SZ&\V6ND7OE[4[77KLV.D3(HO;H,$**'4@\B&`
M^(`=,^@_:O2Z'5=F9L6OGX>"0''*ZKU"MZ/\5#DZK!*49@Q%ECOY>:7Y0TNU
MU-/*.JMJL$LR->NTHEX.%(45"K2HSGO^!]V7V)H,.:/9.<YHRD.(F0E1HURC
M'HW:N>21'B"DF\M?GW^3?G'S,GDSRQ^8NC:SYJD>XCCT&WF)N2]JK-.H0@;H
M$8D>QST4XY`60Z3#VII<V3PX9`9=W5DOGK\RO(7Y9:?9ZKY_\U:?Y4T_4+CZ
MI8W>H2>FLLW`OP78U/%2<$8F7)OU6LPZ6(EED(@[;L=UCS'^6?YI?E#YMU0>
M:X+O\L]=T75+/6_-5C+PBCLA%+#>RI*R$#T@'^+B0",($HR&V[1ES:?5Z6<N
M/]V8D&0[N1^3Y^_YQ/\`R_\`^<:/)>L^<9_R&_,2X\[:C?V5I'YBMYKZ*\%O
M`DDAA<".WAX\F+"I)RS-.<@.(.I[!T>@P3F=+D,R0+WO]`?5/GG\P_)'Y::*
MWF+S[YFL?*VC"184O+Z3AZDK=(XT%7D8@5XJ":;Y5&)D:#OM3J\6FAQY9"(\
MWQE_SE-^;OY9?FU_SBA^;-U^7OG'3?-<5B-)%];VSD3P_P"Y:SH9;>54E4$]
M"5H>V7X8&.06'FNWNT-/J^S,IPS$JX??]0Z<WF/_`#ZY15\F_FWQ4+77=/K0
M4_X]7R>LYAPO84WAR^\?I?HOYX_,CR'^6FF)K'GWS;IGE33Y6X03:A.L32L*
M56*/=Y"*[A0<Q8Q,N3V.IUF'31XLLA$>;SCRI_SE+_SC[YVU:WT+RY^:NBW>
MK7;^G9V,[RV;3.>B1&ZCB#L>P4DGMDI89CF'#P=N:+/+AAE!)^'WT]]RMVK_
M`/_2^_F*NQ5Y)^96F23/;W2*Q2YMWM7*1ZE,0PJ15+*54`HQW=37Y;9Y-_P2
M>S)93#*`:E`P-#4S-[D>G3SC#K_'`WR-C9SM'.MOU?I?-LGY9W7YOZ/I?Y7Z
MSYRO_)_E6QU>?4?/GE6T!MKO7[1XHQ!:>L:/&BR(3(!]I2-J@$:?_@)=L8]+
MIL_9F<>'J(SXXQD.&1C(`'8T;!C\B'`]I.S):XP]9&+^(#^+N%]R._,/1=+\
MN>96\OZ'8Q:9HNB6%A8Z3IT(I'!;P6T:1QH#795`&>3_`/!?)/M+J">['_N(
MN^[+Q1Q::,("HC8#R?0OY0SP6OY?V]Q<S);V\-Q=/+-(P5542&I).PSW'_@1
MY\>#V9ADRR$8QED))-`#BYDEP->"<U#R>-12R:_YP\P^8K>WG;3[N:1+&X%O
M?R(X!55^*Q:-@>*@T+4WZ9XYBRR[7[=U?:..$SBG*0A+@SR$MP!OIS"0/"`:
M,JWW%T[`CP\48'F/,?I?5VD6AL-+L+-J%[>!$D(:1ARI\5#*SO2O\S$Y]5]D
MZ0Z328L)YQB`=Y'>M]YF4^?\Z1/>729)<4B4QS8,'R]_SFC_`.LP?F[_`-LR
MV_ZCK;+L'UAT?M)_QGY?</O#\TO^<%O^<?\`R%^>MIY^?\Q_TEJVC^4+JR.D
M^6H+R6ULS<ZA%*);J00LKF0+`J@AAMUKMF7J<I@13Q'LIV3AU\<GC61&J%D"
MS>^WN>:^6=,_Y4+_`,YMZ1Y:\LWMQ^C?+WGVVT6WD=_WLFF:G)'"T,K"G.D-
MQQ.VY%<D3XF*SW.%AA_)O;`AC.PF!\)&ON+]WOS`\FIYST9;..9;;4+.3U]/
MN'!*\J49'IOQ8>'38YYG[?>QT?:;0>")"&6!XH2/*ZHQE_1D/D0#O5/M.EU'
M@ROH>;YIL-8\[_E=J$EG+"UM%(_*73[E>=K/3;G&P-*D#JIKXY\V:#MCVA]@
MM2<,XF,2;,)CBQ3_`*42/+^*)O\`G<J=Q+'BU4;_`+7T5Y(_,G2/.-;01G3=
M8C3F^GR-R#J.K1/MR`[BE1^.?0_L3_P1]#[2_N@/"U`%F!-V.IA+;BKJ*!'=
M6[J=3HY8=^8[T1^:/_*!>8_^,,?_`">CS(_X)_\`SC>K_JQ_W<4:+^^C^.CS
M_P#(3_CF>8O^8N'_`)-G.!_X`W^)ZO\`KQ_W)<KM3ZH^Y^3/YJ6Y_P"<?/\`
MG/"V\QQ5L]%NO-%CYC5U'%3I^N'AJ`4#L&DG7Z,^C8?O,5/BNOC_`";VT)C:
M)D)?"7U??(/3/^?G'G&74_.WY:_ES8NTQT;39]8N;9-^5SJ4HM[=:=V"V[4_
MUO?(:2-`ES?;C4\>;'@'07_IC7Z/M?=NN>1H_P`M?^<-/,OD5$X2>7/RPU*V
MO1UK='399+IMOYIF<YC"7%D!\WJLVE_+=DRQ?S<1OW\)O[7PK_SZY_Y2W\V_
M^V/I7_)^?,G6<@\K["?WN7W#[RPW_GY=YEU+4?SF\L>5FG<Z5Y<\LPW-G9D_
MNQ=7]Q-ZTM/%DBC7Y+DM)'TVXWMOGE+5QQ_PQB#\23?W!Z7_`,Y`_P#.'7Y6
M?E?_`,XSW'GSR_\`I2S\\>7M.TEM9U,7DCPZF]Y<VT-PD\#DHJ<I2Z!`M"JU
MKD,6>4LE'DYW:_LYIM)V=XL+$XB-F_JL@&Q^IF/_`#Z[_P"4-_-K_MNZ?_U"
MOD=9S#D^PO\`<Y?>/TJ7YM?\X5_G+^=WY[ZAYV\\><-&B_+ZZU40V=K;7=P]
M_9:#"U(X;:%[7T4E9!5OBIS8L>7=AJ(PC0&Z]H>S6KU^L.3+,>'?0FQ'R%5=
M?:^1_P#G,G\F/R3_`"@U3R?:?E)YI&IWU\MW%YJ\OMJ4>HS6;0>D8)F9/BB,
MG)P5;NM5`WR_3Y)3OB>=]I>S=)HI0_+RLF^(6#7*O=>[]B/^<5_,NK^;_P#G
M'K\J-?UZ[>_U:ZT1(;R]E):28VDLELKNQW9F6(%B=R=\P,PJ9?1^PL\LVAQ3
MD;-?<:_0_P#_T_OYBJ&O;VTTVSN]0U"ZBLK"QA>XO;R=Q'%%%$I=Y'=B`JJH
M))/08L92$0230#XE\@^<OS#_`.<FOS+_`,9^7-6N_)__`#C=Y(N;FPTZ%8PL
M_G2ZH8II)!(IXVJ'[)%"#TI)4QNLT>'-@EAS1$A,41Y?CN>=T.LU':&I&;%(
MPP0.W?D/ZOQS^GO.J?DEH=Y<&YL=8U#3Y:U4.XN`OAQ+T?;W;/&.T_\`@*]G
M:G+XN#49<4O,^)7N)J7SD7M8=HS`H@%\^^=M#D\N>8[W2)-0DU1K9(3]=E!#
ML'C5@""S=*TZY\^^V_8DNQNU<FDEE.8Q$?7+8GBB#WRY77-VNFR>)`2JGH7D
M?\L%\V^7K?4KKS#=6EK)-*GZ.C3D@]-J5!9J5/7[.>A^P_\`P,A[0]EPU.75
MSA`RD/#`L>DU>\JW_JN)J=9X4Z$1?>]O\K_EYH/E5TGM&NKR[C!$<]U*6"<N
MO"->*+7QI7/;/9C_`('O9O8$A/"9SF.4IRNKY\,141[ZOS=;FU4\O.@&=YW3
MC.Q5\O?\YH_^LP?F[_VS+;_J.MLNP?6'1^TG_&?E]P^\/D'_`)];?\<G\YQ7
M<7NB5'_/*\R_6<P\W[!_1F]\?]\^6?S((U#_`)S[N$LR+AF_-#181P-?CBN+
M1'7;NK*0?"F70_N?@Z+7>KMO;?\`>Q^\/W#\]^?D\D+8&32)M1&H>H(I4D6.
M-6CI56)#&M#7IGEGMU[>1]EHXC+!++XET01&(,:V)HF]^Y]GTVE\>]ZI7\OZ
MMHGYC^65FOK&WG24M'J.F2$2>C(I(&]`144(84R_V?[6[/\`;3LD3S8X2!L3
MQGU<$A\B-O5&0H[[(RXYZ?)0/N+Y9:&/0?S`CM_+]RUQ%I^L1QZ?,IY%@9%4
MI4?:ZE3XY\MRPP[)]IQC[/F91QZ@"!!N_4!PWUZP/\[XN[OQ,-SZA]1_FC_R
M@7F/_C#'_P`GH\^H/^"?_P`XWJ_ZL?\`=Q=+HO[Z/XZ//_R$_P".9YB_YBX?
M^39S@?\`@#?XGJ_Z\?\`<ERNU/JC[GPE_P`_/_(7*W_+3\S;6&C1/<^6=7N!
MUHX-Y9;^Q6?[\^B-'+F'RKVYTFV/..GI/WC_`'SY9_*:\U;_`)R<_P"<L/RW
MU#S#$9TMAI,^LQRGFK6OEJPB,A;VGF@J1XR9=D`QXS3H>SIR[5[3QRGTX;_S
M`/OK[7[9?\Y!?^2)_.3_`,`K7?\`J`FS7XOK'O?3NV/\2S?U)?<7YD_\^N?^
M4M_-O_MCZ5_R?GS,UG(/#^PG][E]P^\O+?\`GX]&\/\`SD1;2R*5CE\J:9)&
MQ_:59[I21]((R>D^CXN![:`_GQ_4'Z7Z+_\`.8UU;WG_`#AUYQO+:59;:\TS
M0)K:52"'234+%E(/>H-<Q<']X/B]E[22$NRID<B(_P"ZB\$_Y]=_\H;^;7_;
M=T__`*A7RS6<PZKV%_N<OO'Z7A_GW\YOS;_YR\_/7_E27D7S3)Y'\@76I7EC
M:6]N[0>O9Z>LCW-[?-&RR3%DB9DAY!?LKUJV61QQQ0XCN76:OM/5=L:W\KBE
MP0LCX#F3W\N7P\V'_P#.9'_.-GY=_P#..WEO\K;+RE=7NI^8-?GU,^8]8U"<
M-+<+;I;>F4MTXI$@:1J4%>Q8TR6GRF9-N+[3=BX.S<>(8R3(W9)YU73H_4W_
M`)PQ_P#68?RB_P"V7/\`]1MQF%G^LO>>S?\`QGXO<?O+_]3[^8J^!_SPUG6?
M^<A_S;MO^<6_)VI3:=Y)\OQ0ZQ^?GF2T:CFVY*\&CQN-@TIXEO<^$;J<C&."
M/&>?1Y7M/)/M'4C0XS4([Y"/]S^/T%]PZ!H.C^5]%TOR[Y>TZ#2-$T6VCL]+
MTVW7A%##$O%$4>P'4[GJ=\H))-EZ;%BAB@(0%1`H!-\#8^#?SO\`--G:_FAJ
M'EW2K6X\T>;[R"V>S\I:4%ENRGHI6:X8D1VT*]6EF94`[GIGS)[;>P_:7M![
M2ZB6"(AAB(<>:?IQ0`QQOU?Q$=T;/?3F?RQ@TF*,-YY3=0CO([_[$><J#WK\
MEM`UD^6;2\\QZY:WWHW$WU70M(Y_HZVDYU;E.X62[<';F56/^5/VC['_`,#O
M2:'1]D1P:+*<^.,YCQ".'CE?JX1_,OZ>I&[A9HY\F3CSU$_S1RC[S_$?D.X/
M>,[A+L5=BKY>_P"<T?\`UF#\W?\`MF6W_4=;9=@^L.C]I/\`C/R^X?>'Y6?\
MX=_DIYU_-#1/S*U[\M/S2U3\K_/7E>;3[:PNK262.SO8+Q)VDAN_1(<4,0*L
M`U-_A/49FHR")`(L/`^S79F750R3PY3CG&N7(W?.M^G['UI_SCI_S@;YJ\A_
MF?I_YH_FSYMTW7;_`$&ZEU'2M,TR2YN6N-0DY4NKNYN8X6)1F+@!26:A+;4-
M.74B4:B'H>QO93)IM0,^HF)$&P!9L]Y)`]_O?I!YE\M:;YJTJ72M31C$Y#PS
MIM)%(OV70GN*_2,Y3VD]F])V_HY:74CTG<$?5"0Y2CY_818+WV'-+%+BB^?I
M_P`D/-%K/*NE:[:-;2?#ZK/-`[+X.J*X/WYX!F_X"7;&GR2&DU6,P.UDSA*O
M,1$A]KM1VEC(]43;-_(_Y0P>7;^#6-9O4U*_M3RL[>%2((G[.2V[$=MA3.V]
MB/\`@18NQ=3'6:S(,N6&\8Q%0B?YV^\B.FP`Y[FJQM3KSD'#$4'HOG#1)_,?
MEO5-%MIH[>>_1$CFEKP7C(KFO&IZ+GHGM=V+D[:[*S:+'(1ED``)NA4A+>M^
MCB:?(,<Q(]&-?EOY)OO)5IJEO?7D%XU_-'+&T`8!0BE2#R`SF_\`@<>Q6H]F
M,&;'GR1F<D@1PWM0(WL!NUFI&8@@53%O^<COR?;\\_RE\P_E];7EOINJWLEK
M=Z'J=VK-#;W=K,LBLX0%J,@9#05HV>F8I\$K>?[9[._/Z:6&Z)H@]Q!_5L^=
M?^<1_P#G#K7?^<?/-_F?SAYL\QZ3YBO]2TI-+T5=-CF'H(\PEN6<SHN[>G&!
MQ[5KEN?/X@H.F]GO9N79N262<A(D4*^WF/(/L7\S?*UWYX_+GSWY,L+F&ROO
M->@:CI%G=W`8Q12WEM)"CR!`6XJ7J:;TRB!X9`O1Z[`=1I\F(&C*)'S%/DG_
M`)P__P"<4?-__..>M^==4\R^9]'U^+S/8V=K:QZ8MPK1M;22.Q?UD44(<4IE
MV?,,@%//^SO8&3LR<Y3D)<0'*_U(_P#YR]_YQ'F_YR'/E[S)Y7UNS\O^=_+M
MN]@6U%9#:7MB[F58I'B5WC:)RQ1@K#XF!'0AP9_#V/)E[1>SW\I<,X2$9QVW
MY$?L>#:3_P`X'_G)KWY?WWE?\SOSK?58]&T]K?\`+GR;;WM]/HMC=;"*>Y:5
M$9EB6H2-(]OYJ#CEAU,0;B'5XO9759,!QZC-=#TQ!/"/?[NFSZ5_YQ`_YQP\
MS?\`..>A>==*\R^8-,U^7S/J-K>6DNF+,JQK!"T;*_K*IJ2:BF59\HR%W7L[
MV-D[,A.,Y"7$1R?)GG7_`)][?FEI7YFWWG7\EOS$TO0K&?4YM3T2>\N+RQU'
M3'G9G:-);:&8.J<RH:JDKLPZUNCJH\-2#S^J]D-3'4G+IL@B+L62#'Y`H[SQ
M_P`^[_S+\Z6&EZYK?YV#S;^8]Q+)_B35M>-U):):A1Z$%F:2R_"W(DMQ!KLB
MTW8ZH1Y#9GJ_8[/J(B4\W%DZF5U70#F?QR?H3^0?Y=ZK^4WY0^2?R[UN_M-3
MU/RO:S6US?V(D$$O.YEF4H)0K?9<`U'7,7)+BD2]?V5HY:330PR()C?+WDO_
MU?NEYU\X:+Y"\MWOFKS#=)8Z-ITMK'?7LAXQPK=7,5L)';LJM*"Q[#)1B9&@
MT:G40T^,Y)F@*^T@?I>6_DE^45I^5UU^:WF!]8MM?NOS0\WWGF@:^GVS87*J
M]M;RO4J?19I*%3Q(:NU:"62?%0[@X'9G9XTARSXN+Q)F5^1Y#X;I=^9/_.5O
MY'_EB9++5/.5OK_F.O"U\H^7O]RFHS2G98A'`66-B?\`?C+ACAE+HQUG;NDT
MNQGQ2_FQ]1^SE\:>7Z9?_P#.3O\`SD&WK-;R_P#.,OY73T*R<5N?..HPL*_!
MZ@$=B&_F*<Q7;EDCP0\S]CA0GK^T-_\`%\?_`$L/_$_?[V?:7_SCROEG3+G0
M_*%U8Z%I=]+ZVKW#^O=:EJD__+1J=_,QFN9"=_B/$?LJ,\A]L_9'V@]I"<<]
M7CQ:>]L<1*CW<9_B/RCY=7J.S,.D[/C6.!XCSD=Y$^9>A^4/)GG7RJ+2PC\R
MV,VAQ7'JW-E]6)<JQK(J.34$X/9'V.[>[`&/3QUF*6F$^*4.#>B?4(RYB_L+
MEZC48LMGA-^]ZYGK#@NQ5V*O)?SU_+B]_-S\IO.GY<Z?J<.C7GFFUBMX-3N(
MVEBB,=Q%,2R(0341TV.3QRX9`N!VIHSK--/"#1E6_P`07BO_`#B/_P`XRZW_
M`,XWV?GJUUGS58^9SYMGL)K=[*WDMQ"+-)U8-ZC-7EZHI3PRS/F\2G5^SW8<
MNRQ,2D)<5<O*_P!;[$RAZ-V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*O
M_];[5_G7_P`J^_Y51Y[_`.5J_P#DO?T5+_B>G/GZ%1Q]+T_C]3U./I\=^=,G
MCOB%<W![2\'\M/Q_[NM_V>=\O-^,VBK_`,XBBWB-Y-_SD0_D3FW!+B*V71@M
M=N36DC,5I_**YFGQ/*_B^<XOY,K?\QX?GP\/V/TI_P"<<?\`H3OTH?\`E0O^
M%OTUP^+G7]/=/BY_7_\`3/G3X<QLOB?Q/:=C_P`E[?E>'B_V?^R]3[!RAZ!V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*O__9
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
